Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2019-06-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/5/1/e000692corr1.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104523595448320 |
|---|---|
| collection | DOAJ |
| format | Article |
| id | doaj-art-1b89d22c405d4fe3bcf035e20cfebed2 |
| institution | DOAJ |
| issn | 2056-5933 |
| language | English |
| publishDate | 2019-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-1b89d22c405d4fe3bcf035e20cfebed22025-08-20T02:39:19ZengBMJ Publishing GroupRMD Open2056-59332019-06-015110.1136/rmdopen-2018-000692corr1Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorshttps://rmdopen.bmj.com/content/5/1/e000692corr1.full |
| spellingShingle | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors RMD Open |
| title | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| title_full | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| title_fullStr | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| title_full_unstemmed | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| title_short | Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| title_sort | correction ixekizumab is efficacious when used alone or when added to conventional synthetic disease modifying antirheumatic drugs cdmards in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors |
| url | https://rmdopen.bmj.com/content/5/1/e000692corr1.full |